SCHEMBL6497498

SCHEMBL6497498

CNC(=O)OCC(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.45
CHRNA4 P43681 2/20 0.45
NFKB1 P19838 2/20 0.45
CHRM2 P08172 1/20 0.45
CHRM4 P08173 1/20 0.45
CHRM5 P08912 1/20 0.45
CYP2D6 P10635 1/20 0.45
CHRM1 P11229 1/20 0.45
CHRM3 P20309 1/20 0.45
MAPK1 P28482 1/20 0.45
CHRNA7 P36544 1/20 0.45
LMNA P02545 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
APEX1 P27695 1/20 0.43
EPHX1 P07099 1/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.36
APOBEC3A P31941 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
TDP1 Q9NUW8 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18736915 0.85 CHRNB2 (0.45) CHRNB2CHRNA4NFKB1CHRM2CHRM4
SCHEMBL20501494 0.83 CHRNB2 (0.43) CHRNB2CHRNA4NFKB1CHRM2CHRM4
SCHEMBL5247104 0.82 CHRNB2 (0.39) CHRNB2CHRNA4NFKB1CHRM2CHRM4
SCHEMBL12845027 0.82 MAPK1 (0.46) CHRNB2CHRNA4NFKB1CHRM2CHRM4
SCHEMBL15949860 0.82 KMT2A (0.44) NFKB1LMNAKMT2ATDP1TSHR
SCHEMBL14330807 0.81 CHRNB2 (0.42) CHRNB2CHRNA4NFKB1CHRM2CHRM4
SCHEMBL17035462 0.81 CHRNB2 (0.42) CHRNB2CHRNA4NFKB1CHRM2CHRM4
SCHEMBL5247568 0.79 NFKB1 (0.41) CHRNB2CHRNA4NFKB1CHRM2CHRM4
SCHEMBL13660651 0.79 CYP2D6 (0.41) CHRNB2CHRNA4NFKB1CHRM2CHRM4
SCHEMBL13480401 0.79 CHRNB2 (0.41) CHRNB2CHRNA4NFKB1CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382920-A1 SHMT Inhibitors THE TRUSTEES OF PRINCETON UNIVERSITY 2023-11-30 US disclosed
US-11718626-B2 Macrocyclic compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2023-08-08 US disclosed
US-20190092781-A1 FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC (US) 2019-03-28 US disclosed
US-10202378-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-02-12 US disclosed
US-20190023716-A1 FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC (US) 2019-01-24 US disclosed
US-9944613-B2 Fumagillol spirocyclic compounds and fused bicyclic compounds and methods of making and using same ZAFGEN, INC. (US) 2018-04-17 US disclosed
US-20180079737-A1 FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC (US) 2018-03-22 US disclosed
US-9199959-B2 HIV replication inhibitor SHIONOGI & CO., LTD. (JP) 2015-12-01 US disclosed
US-20140249306-A1 HIV REPLICATION INHIBITOR SHIONOGI & CO., LTD. (JP) 2014-09-04 US disclosed
US-8569267-B2 Tetracyclic tetrahydrofuran derivatives containing cyclic amine side chain JANSSEN PHARMACEUTICA, NV (BE) 2013-10-29 US disclosed
EP-2177523-A1 Novel macrocyclic inhibitors of hepatitis c virus replication Intermune, Inc. (US) 2010-04-21 EP disclosed
US-20080262076-A1 Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain JANSSEN PHARMACEUTICA, NV (BE) 2008-10-23 US disclosed
US-20080262076-A1 Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain JANSSEN PHARMACEUTICA, NV (BE) 2008-10-23 US disclosed
WO-2005016883-A2 ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF ICOS CORPORATION (US) 2005-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718626-B2 Macrocyclic compounds for treatment of medical disorders CFD, TFPI, CFH CHRNB2 4194/4885CHRNA4 4415/4885NFKB1 181/4885
US-20080262076-A1 Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain HTR2C, HTR2A, HTR5A CHRNB2 272/4885CHRNA4 375/4885NFKB1 2509/4885
US-20180079737-A1 FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME METAP2, FOLH1, FAP CHRNB2 4388/4885CHRNA4 4790/4885NFKB1 2570/4885
US-10202378-B2 Therapeutic compounds and uses thereof TAF1, TAF1L, TAF1B CHRNB2 4450/4885CHRNA4 4637/4885NFKB1 657/4885
US-20190092781-A1 FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME METAP2, FOLH1, FAP CHRNB2 4388/4885CHRNA4 4790/4885NFKB1 2570/4885
US-20190023716-A1 FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME METAP2, FOLH1, FAP CHRNB2 4388/4885CHRNA4 4790/4885NFKB1 2570/4885
US-20140249306-A1 HIV REPLICATION INHIBITOR SSU72, RTF2, ZC3HAV1 CHRNB2 3250/4885CHRNA4 3630/4885NFKB1 1315/4885
US-20230382920-A1 SHMT Inhibitors SHMT1, SHMT2, BHMT CHRNB2 4850/4885CHRNA4 4860/4885NFKB1 2034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.